Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Assembly Biosciences
Biotech
Gilead turns down Assembly's ph. 1-stage HBV antiviral
Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner on other assets.
James Waldron
Mar 20, 2026 5:14am
Gilead pays $35M to license pair of HSV assets from Assembly Bio
Dec 22, 2025 10:35am
Gilead backs out of option to buy immunotherapy-focused Tizona
Feb 6, 2024 7:15pm
Hepatitis B drug developers chart slow progress, just like hep C
Nov 14, 2023 9:05am
Gene editor Metagenomi adds C-suite execs—Chutes & Ladders
Nov 10, 2023 9:30am
Gilead pays $100M for first dibs on all Assembly Bio assets
Oct 17, 2023 7:00am
